Skip to main content
Erschienen in: Journal of Neural Transmission 8/2014

01.08.2014 | Neurology and Preclinical Neurological Studies - Review article

A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease

verfasst von: Giulia Ambrosi, Silvia Cerri, Fabio Blandini

Erschienen in: Journal of Neural Transmission | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Increased levels of extracellular glutamate and hyperactivation of glutamatergic receptors in the basal ganglia trigger a critical cascade of events involving both intracellular pathways and cell-to-cell interactions that affect cell viability and promote neuronal death. The ensemble of these glutamate-triggered events is responsible for excitotoxicity, a phenomenon involved in several pathological conditions affecting the central nervous system, including a neurodegenerative disease such as Parkinson’s disease (PD). PD is an age-related disorder caused by the degeneration of dopaminergic neurons within the substantia nigra pars compacta, with a miscellaneous pathogenic background. Glutamate-mediated excitotoxicity may be involved in a lethal vicious cycle, which critically contributes to the exacerbation of nigrostriatal degeneration in PD. Since excitotoxicity is a glutamate-receptor-mediated phenomenon, growing interest and work have been dedicated to the research for modulators of glutamate neurotransmission that might enable new therapeutic interventions to slow down the neurodegenerative process and ameliorate PD motor symptoms.
Literatur
Zurück zum Zitat Addy C, Assaid C, Hreniuk D et al (2009) Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson’s disease. J Clin Pharmacol 49:856–864. doi:10.1177/0091270009336735 PubMed Addy C, Assaid C, Hreniuk D et al (2009) Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson’s disease. J Clin Pharmacol 49:856–864. doi:10.​1177/​0091270009336735​ PubMed
Zurück zum Zitat Alagarsamy S, Marino MJ, Rouse ST et al (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2:234–240. doi:10.1038/6338 PubMed Alagarsamy S, Marino MJ, Rouse ST et al (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2:234–240. doi:10.​1038/​6338 PubMed
Zurück zum Zitat Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42:733–738PubMed Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42:733–738PubMed
Zurück zum Zitat Ambrosi G, Armentero M-T, Levandis G et al (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson’s disease. Brain Res Bull 82:29–38. doi:10.1016/j.brainresbull.2010.01.011 PubMed Ambrosi G, Armentero M-T, Levandis G et al (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson’s disease. Brain Res Bull 82:29–38. doi:10.​1016/​j.​brainresbull.​2010.​01.​011 PubMed
Zurück zum Zitat Armentero M-T, Fancellu R, Nappi G et al (2006) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson’s disease. Neurobiol Dis 22:1–9. doi:10.1016/j.nbd.2005.09.010 PubMed Armentero M-T, Fancellu R, Nappi G et al (2006) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson’s disease. Neurobiol Dis 22:1–9. doi:10.​1016/​j.​nbd.​2005.​09.​010 PubMed
Zurück zum Zitat Bak LK, Schousboe A, Sonnewald U, Waagepetersen HS (2006) Glucose is necessary to maintain neurotransmitter homeostasis during synaptic activity in cultured glutamatergic neurons. J Cereb Blood Flow Metab 26:1285–1297. doi:10.1038/sj.jcbfm.9600281 PubMed Bak LK, Schousboe A, Sonnewald U, Waagepetersen HS (2006) Glucose is necessary to maintain neurotransmitter homeostasis during synaptic activity in cultured glutamatergic neurons. J Cereb Blood Flow Metab 26:1285–1297. doi:10.​1038/​sj.​jcbfm.​9600281 PubMed
Zurück zum Zitat Battaglia G, Busceti CL, Pontarelli F et al (2003) Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45:155–166PubMed Battaglia G, Busceti CL, Pontarelli F et al (2003) Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45:155–166PubMed
Zurück zum Zitat Battaglia G, Busceti CL, Molinaro G et al (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24:828–835. doi:10.1523/JNEUROSCI.3831-03.2004 PubMed Battaglia G, Busceti CL, Molinaro G et al (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24:828–835. doi:10.​1523/​JNEUROSCI.​3831-03.​2004 PubMed
Zurück zum Zitat Battaglia G, Busceti CL, Molinaro G et al (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26:7222–7229. doi:10.1523/JNEUROSCI.1595-06.2006 PubMed Battaglia G, Busceti CL, Molinaro G et al (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26:7222–7229. doi:10.​1523/​JNEUROSCI.​1595-06.​2006 PubMed
Zurück zum Zitat Berg D, Godau J, Trenkwalder C et al (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243–1250. doi:10.1002/mds.23616 PubMed Berg D, Godau J, Trenkwalder C et al (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243–1250. doi:10.​1002/​mds.​23616 PubMed
Zurück zum Zitat Blandini F, Nappi G, Greenamyre JT (2001) Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson’s disease. Ann Neurol 49:525–529PubMed Blandini F, Nappi G, Greenamyre JT (2001) Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson’s disease. Ann Neurol 49:525–529PubMed
Zurück zum Zitat Breysse N, Baunez C, Spooren W et al (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669–5678PubMed Breysse N, Baunez C, Spooren W et al (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669–5678PubMed
Zurück zum Zitat Chan H, Paur H, Vernon AC et al (2010) Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson’s disease. Parkinsons Dis. doi:10.4061/2010/190450 PubMedCentralPubMed Chan H, Paur H, Vernon AC et al (2010) Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson’s disease. Parkinsons Dis. doi:10.​4061/​2010/​190450 PubMedCentralPubMed
Zurück zum Zitat Clarke CE, Cooper JA, Holdich TAA (2001) Randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson’s disease with response fluctuations. Clin Neuropharmacol 24:133–138PubMed Clarke CE, Cooper JA, Holdich TAA (2001) Randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson’s disease with response fluctuations. Clin Neuropharmacol 24:133–138PubMed
Zurück zum Zitat Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29:1451–1461. doi:10.1038/sj.npp.1300444 PubMed Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29:1451–1461. doi:10.​1038/​sj.​npp.​1300444 PubMed
Zurück zum Zitat Dall’Olio R, Rimondini R, Gandolfi O (1995) The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 118:310–315PubMed Dall’Olio R, Rimondini R, Gandolfi O (1995) The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 118:310–315PubMed
Zurück zum Zitat De Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445–452PubMed De Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445–452PubMed
Zurück zum Zitat Dunah AW, Wang Y, Yasuda RP et al (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Mol Pharmacol 57:342–352PubMed Dunah AW, Wang Y, Yasuda RP et al (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Mol Pharmacol 57:342–352PubMed
Zurück zum Zitat Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson’s disease. CNS drugs 26:1017–1032. doi:10.1007/s40263-012-0016-z PubMed Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson’s disease. CNS drugs 26:1017–1032. doi:10.​1007/​s40263-012-0016-z PubMed
Zurück zum Zitat Eggert K, Squillacote D, Barone P et al (2010) Safety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo-controlled study. Mov Disord 25:896–905. doi:10.1002/mds.22974 PubMed Eggert K, Squillacote D, Barone P et al (2010) Safety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo-controlled study. Mov Disord 25:896–905. doi:10.​1002/​mds.​22974 PubMed
Zurück zum Zitat Elahi B, Phielipp N, Chen R (2012) N-Methyl-d-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol 39:465–472 Elahi B, Phielipp N, Chen R (2012) N-Methyl-d-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol 39:465–472
Zurück zum Zitat Gao H-C, Zhu H, Song C-Y et al (2013) Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson’s rat. Mol Neurobiol 47:123–130. doi:10.1007/s12035-012-8336-z PubMed Gao H-C, Zhu H, Song C-Y et al (2013) Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson’s rat. Mol Neurobiol 47:123–130. doi:10.​1007/​s12035-012-8336-z PubMed
Zurück zum Zitat Greco B, Lopez S, van der Putten H et al (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson’s disease. J Pharmacol Exp Ther 332:1064–1071. doi:10.1124/jpet.109.162115 PubMed Greco B, Lopez S, van der Putten H et al (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson’s disease. J Pharmacol Exp Ther 332:1064–1071. doi:10.​1124/​jpet.​109.​162115 PubMed
Zurück zum Zitat Hsieh M-H, Ho S-C, Yeh K-Y et al (2012) Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson’s disease rat model. Pharmacol Biochem Behav 102:64–71. doi:10.1016/j.pbb.2012.03.022 PubMed Hsieh M-H, Ho S-C, Yeh K-Y et al (2012) Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson’s disease rat model. Pharmacol Biochem Behav 102:64–71. doi:10.​1016/​j.​pbb.​2012.​03.​022 PubMed
Zurück zum Zitat Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731–748PubMedCentralPubMed Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731–748PubMedCentralPubMed
Zurück zum Zitat Huettner JE (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70:387–407PubMed Huettner JE (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70:387–407PubMed
Zurück zum Zitat Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets 8:475–491PubMedCentralPubMed Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets 8:475–491PubMedCentralPubMed
Zurück zum Zitat Kennedy MB (1997) The postsynaptic density at glutamatergic synapses. Trends Neurosci 20:264–268PubMed Kennedy MB (1997) The postsynaptic density at glutamatergic synapses. Trends Neurosci 20:264–268PubMed
Zurück zum Zitat Koutsilieri E, Riederer P (2007) Excitotoxicity and new antiglutamatergic strategies in Parkinson’s disease and Alzheimer’s disease. Parkinsonism Relat Disord 13(Suppl 3):S329–S331. doi:10.1016/S1353-8020(08)70025-7 PubMed Koutsilieri E, Riederer P (2007) Excitotoxicity and new antiglutamatergic strategies in Parkinson’s disease and Alzheimer’s disease. Parkinsonism Relat Disord 13(Suppl 3):S329–S331. doi:10.​1016/​S1353-8020(08)70025-7 PubMed
Zurück zum Zitat Le Poul E, Boléa C, Girard F et al (2012) A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease. J Pharmacol Exp Ther 343:167–177. doi:10.1124/jpet.112.196063 PubMed Le Poul E, Boléa C, Girard F et al (2012) A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease. J Pharmacol Exp Ther 343:167–177. doi:10.​1124/​jpet.​112.​196063 PubMed
Zurück zum Zitat Lee M (2013) Neurotransmitters and microglial-mediated neuroinflammation. Curr Protein Pept Sci 14:21–32PubMed Lee M (2013) Neurotransmitters and microglial-mediated neuroinflammation. Curr Protein Pept Sci 14:21–32PubMed
Zurück zum Zitat Lees A, Fahn S, Eggert KM et al (2012) Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Mov Disord 27:284–288. doi:10.1002/mds.23983 PubMed Lees A, Fahn S, Eggert KM et al (2012) Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Mov Disord 27:284–288. doi:10.​1002/​mds.​23983 PubMed
Zurück zum Zitat Levandis G, Bazzini E, Armentero M-T et al (2008) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neurobiol Dis 29:161–168. doi:10.1016/j.nbd.2007.08.011 PubMed Levandis G, Bazzini E, Armentero M-T et al (2008) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neurobiol Dis 29:161–168. doi:10.​1016/​j.​nbd.​2007.​08.​011 PubMed
Zurück zum Zitat McNaught KS, Jenner P (2000) Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem Pharmacol 60:979–988PubMed McNaught KS, Jenner P (2000) Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem Pharmacol 60:979–988PubMed
Zurück zum Zitat Merino M, Vizuete ML, Cano J, Machado A (1999) The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J Neurochem 73:750–757PubMed Merino M, Vizuete ML, Cano J, Machado A (1999) The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J Neurochem 73:750–757PubMed
Zurück zum Zitat Morales I, Rodriguez M (2012) Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia 60:1481–1494. doi:10.1002/glia.22368 PubMed Morales I, Rodriguez M (2012) Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia 60:1481–1494. doi:10.​1002/​glia.​22368 PubMed
Zurück zum Zitat Murray TK, Messenger MJ, Ward MA et al (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson’s disease. Pharmacol Biochem Behav 73:455–466PubMed Murray TK, Messenger MJ, Ward MA et al (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson’s disease. Pharmacol Biochem Behav 73:455–466PubMed
Zurück zum Zitat Noda M, Beppu K (2013) Possible contribution of microglial glutamate receptors to inflammatory response upon neurodegenerative diseases. J Neurol Dis 1:131. doi:10.4172/2329-6895.1000131 Noda M, Beppu K (2013) Possible contribution of microglial glutamate receptors to inflammatory response upon neurodegenerative diseases. J Neurol Dis 1:131. doi:10.​4172/​2329-6895.​1000131
Zurück zum Zitat Ossowska K, Konieczny J, Wolfarth S, Pilc A (2005) MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 49:447–455. doi:10.1016/j.neuropharm.2005.04.002 PubMed Ossowska K, Konieczny J, Wolfarth S, Pilc A (2005) MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 49:447–455. doi:10.​1016/​j.​neuropharm.​2005.​04.​002 PubMed
Zurück zum Zitat Paillé V, Picconi B, Bagetta V et al (2010) Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30:14182–14193. doi:10.1523/JNEUROSCI.2149-10.2010 PubMed Paillé V, Picconi B, Bagetta V et al (2010) Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30:14182–14193. doi:10.​1523/​JNEUROSCI.​2149-10.​2010 PubMed
Zurück zum Zitat Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383–400. doi:10.1038/nrn3504 PubMed Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383–400. doi:10.​1038/​nrn3504 PubMed
Zurück zum Zitat Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91:10625–10629PubMedCentralPubMed Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91:10625–10629PubMedCentralPubMed
Zurück zum Zitat Rodriguez-Rodriguez P, Fernandez E, Almeida A, Bolaños JP (2012) Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ 19:1582–1589. doi:10.1038/cdd.2012.33 PubMedCentralPubMed Rodriguez-Rodriguez P, Fernandez E, Almeida A, Bolaños JP (2012) Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ 19:1582–1589. doi:10.​1038/​cdd.​2012.​33 PubMedCentralPubMed
Zurück zum Zitat Rothstein JD, Dykes-Hoberg M, Pardo CA et al (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675–686PubMed Rothstein JD, Dykes-Hoberg M, Pardo CA et al (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675–686PubMed
Zurück zum Zitat Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis 3:255–269. doi:10.3233/JPD-130186 PubMed Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis 3:255–269. doi:10.​3233/​JPD-130186 PubMed
Zurück zum Zitat Salvatore MF, Davis RW, Arnold JC, Chotibut T (2012) Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser(19). Exp Neurol 234:428–436. doi:10.1016/j.expneurol.2012.01.012 PubMed Salvatore MF, Davis RW, Arnold JC, Chotibut T (2012) Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser(19). Exp Neurol 234:428–436. doi:10.​1016/​j.​expneurol.​2012.​01.​012 PubMed
Zurück zum Zitat Sattler R, Charlton MP, Hafner M, Tymianski M (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71:2349–2364PubMed Sattler R, Charlton MP, Hafner M, Tymianski M (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71:2349–2364PubMed
Zurück zum Zitat Shoulson I, Penney J, McDermott M et al (2001) A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease. Neurology 56:455–462PubMed Shoulson I, Penney J, McDermott M et al (2001) A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease. Neurology 56:455–462PubMed
Zurück zum Zitat Silva-Adaya D, Pérez-De La Cruz V, Villeda-Hernández J et al (2011) Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33:303–312. doi:10.1016/j.ntt.2010.10.002 PubMed Silva-Adaya D, Pérez-De La Cruz V, Villeda-Hernández J et al (2011) Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33:303–312. doi:10.​1016/​j.​ntt.​2010.​10.​002 PubMed
Zurück zum Zitat Spieker S, Breit S, Klockgether T, Dichgans J (1999) Tremorlytic activity of budipine in Parkinson’s disease. J Neural Transm Suppl 56:165–172PubMed Spieker S, Breit S, Klockgether T, Dichgans J (1999) Tremorlytic activity of budipine in Parkinson’s disease. J Neural Transm Suppl 56:165–172PubMed
Zurück zum Zitat Stocchi F, Rascol O, Destee A et al (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. doi:10.1002/mds.25561 Stocchi F, Rascol O, Destee A et al (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. doi:10.​1002/​mds.​25561
Zurück zum Zitat Tavares RG, Tasca CI, Santos CES et al (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621–627PubMed Tavares RG, Tasca CI, Santos CES et al (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621–627PubMed
Zurück zum Zitat Turski L, Bressler K, Rettig KJ et al (1991) Protection of substantia nigra from MPP + neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349:414–418. doi:10.1038/349414a0 PubMed Turski L, Bressler K, Rettig KJ et al (1991) Protection of substantia nigra from MPP + neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349:414–418. doi:10.​1038/​349414a0 PubMed
Zurück zum Zitat Varanese S, Howard J, Di Rocco A (2010) NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson’s disease. Mov Disord 25:508–510. doi:10.1002/mds.22917 PubMed Varanese S, Howard J, Di Rocco A (2010) NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson’s disease. Mov Disord 25:508–510. doi:10.​1002/​mds.​22917 PubMed
Zurück zum Zitat Vidal E, Fukushima FB, Valle AP, Villas Boas PJF (2013) Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementia. J Am Geriatr Soc 61:170–172. doi:10.1111/jgs.12058 PubMed Vidal E, Fukushima FB, Valle AP, Villas Boas PJF (2013) Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementia. J Am Geriatr Soc 61:170–172. doi:10.​1111/​jgs.​12058 PubMed
Zurück zum Zitat Wild AR, Akyol E, Brothwell SLC et al (2013) Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones. Neuropharmacology 73C:138–146. doi:10.1016/j.neuropharm.2013.05.013 Wild AR, Akyol E, Brothwell SLC et al (2013) Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones. Neuropharmacology 73C:138–146. doi:10.​1016/​j.​neuropharm.​2013.​05.​013
Zurück zum Zitat Wolf E, Seppi K, Katzenschlager R et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 25:1357–1363. doi:10.1002/mds.23034 PubMed Wolf E, Seppi K, Katzenschlager R et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 25:1357–1363. doi:10.​1002/​mds.​23034 PubMed
Metadaten
Titel
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
verfasst von
Giulia Ambrosi
Silvia Cerri
Fabio Blandini
Publikationsdatum
01.08.2014
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 8/2014
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-013-1149-z

Weitere Artikel der Ausgabe 8/2014

Journal of Neural Transmission 8/2014 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Review Article

Glutamate as a neurotransmitter in the healthy brain

Translational Neurosciences - Review article

Glutamatergic autoencephalitides: an emerging field

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.